Meiragtx Holdings vs Sinovac Biotech
Sinovac Biotech is the larger business, with $386m of revenue in fiscal 2025 against $81.4m for Meiragtx Holdings (4.7 times as much). Meiragtx Holdings grew faster (144.6% against 6.8%). Sinovac Biotech kept more of each dollar of sales as profit: a net margin of -15.5% against -140.3%.
| Latest fiscal year | Meiragtx HoldingsMGTX, 2025 | Sinovac BiotechSVA, 2025 |
|---|---|---|
| Revenue | $81.4m | $386m |
| Revenue growth | 144.6% | 6.8% |
| Net income | −$114m | −$59.7m |
| Operating margin | -130.2% | -127.0% |
| Net margin | -140.3% | -15.5% |
| Return on equity | — | -0.9% |
| Free cash flow | −$50.2m | −$561m |
| Cash | $65.9m | $488m |
| Total debt | $74.3m | $495m |
| Debt to equity | — | 11.1% |
| Dividend per share | — | — |
| Dividend yield | — | 760.2% |
| Share buybacks | — | — |
| Employees | 403 | — |
| Market value | $887m | $465m |
| Price vs our value range | — | — |
| Moat score | 9 (Weak) | — |
| Insider trades, 12 months | 0 buys, 10 sales | 0 buys, 0 sales |